Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Nat Rev Urol ; 19(5): 263-279, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-35260844

RESUMEN

Measuring treatment-related quality of life (QOL) has become an increasingly requisite component of delivering high-quality care for patients with prostate cancer. Patient-reported outcome measures (PROMs) have, therefore, become an important tool for understanding the adverse effects of radical prostate cancer treatment and have been widely integrated into clinical practice. By providing real-time symptom monitoring and improved clinical feedback to patients and providers, PRO assessment has led to meaningful gains in prostate cancer care delivery and quality improvement worldwide. By providing an avenue for benchmarking, collaboration and population health monitoring, PROMs have delivered substantial improvements beyond providing individual symptom feedback. However, multilevel barriers exist that need to be addressed before the routine implementation of PROMs is achieved. Improvements in collection, interpretation, standardization and reporting will be crucial for the continued implementation of PROM instruments in prostate cancer pathways.


Asunto(s)
Medición de Resultados Informados por el Paciente , Neoplasias de la Próstata , Atención a la Salud , Humanos , Masculino , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/terapia , Mejoramiento de la Calidad , Calidad de Vida
3.
Urology ; 164: 55-62, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-34813829

RESUMEN

OBJECTIVE: To conduct a nationwide evaluation of student and program director (PD) perspectives of virtual subinternships that took place during the COVID-19 pandemic. MATERIALS AND METHODS: In December 2020, we distributed anonymous surveys to all 534 urology residency applicants and 161 urology PDs at academic medical centers across the United States to evaluate virtual subinternships. Surveys assessed curriculum composition, goals, satisfaction, barriers, and future reusability. The primary outcome was overall satisfaction with the subinternship, evaluated on a 5-point Likert scale. RESULTS: The survey was completed by 174 students (33%) and 82 PDs (51%), including 81 students (47%) and 32 PDs (41%) who participated in virtual subinternships at 29 institutions. Overall, 77% of students and 78% of PDs rated the electives "excellent" or "very good." On ordinal logistic regression, higher student ratings were associated with duration ≥3 weeks (odds ratio [OR] 4.64, P = .003) and class size ≤4 students (OR 3.33, P = .015). Higher PD ratings were associated with full-time electives (OR 11.18, P = .019), class size ≤4 students (OR 13.99, P = .042), and utilization of the standardized Guidebook from the Society of Academic Urologists (OR 11.89, P = .038). The most commonly reported challenge to the subinternship's efficacy was lack of hands-on learning (87% of students and 81% of PDs). Looking forward, 45% of students and 66% of PDs recommended incorporating virtual components into future electives. CONCLUSION: The virtual subinternship was a coordinated nationwide initiative to provide urologic education to medical students during a pandemic. The most successful courses were structured with longer duration, full-time commitment, and small class size.


Asunto(s)
COVID-19 , Internado y Residencia , Estudiantes de Medicina , Urología , COVID-19/epidemiología , Curriculum , Humanos , Pandemias , Estados Unidos , Urología/educación
4.
Implement Sci Commun ; 2(1): 124, 2021 Oct 28.
Artículo en Inglés | MEDLINE | ID: mdl-34711274

RESUMEN

BACKGROUND: Men with prostate cancer are often treated with the suppression of testosterone through long-acting injectable drugs termed chemical castration or androgen deprivation therapy (ADT). In most cases, ADT is not an appropriate treatment for localized prostate cancer, indicating low-value care. Guided by the Theoretical Domains Framework (TDF) and the Behavior Change Wheel's Capability, Opportunity, Motivation Model (COM-B), we conducted a qualitative study to identify behavioral determinants of low-value ADT use to manage localized prostate cancer, and theory-based opportunities for de-implementation strategy development. METHODS: We used national cancer registry and administrative data from 2016 to 2017 to examine the variation in low-value ADT use across Veterans Health Administration facilities. Using purposive sampling, we selected high- and low-performing sites to conduct 20 urology provider interviews regarding low-value ADT. We coded transcripts into TDF domains and mapped content to the COM-B model to generate a conceptual framework for addressing low-value ADT practices. RESULTS: Our interview findings reflected provider perspectives on prescribing ADT as low-value localized prostate cancer treatment, including barriers and facilitators to de-implementing low-value ADT. We characterized providers as belonging in 1 of 3 categories with respect to low-value ADT use: 1) never prescribe 2); willing, under some circumstances, to prescribe: and 3) prescribe as an acceptable treatment option. Provider capability to prescribe low-value ADT depended on their knowledge of localized prostate cancer treatment options (knowledge) coupled with interpersonal skills to engage patients in educational discussion (skills). Provider opportunity to prescribe low-value ADT centered on the environmental resources to inform ADT decisions (e.g., multi-disciplinary review), perceived guideline availability, and social roles and influences regarding ADT practices, such as prior training. Provider motivation involved goals of ADT use, including patient preferences, beliefs in capabilities/professional confidence, and beliefs about the consequences of prescribing or not prescribing ADT. CONCLUSIONS: Use of the TDF domains and the COM-B model enabled us to conceptualize provider behavior with respect to low-value ADT use and clarify possible areas for intervention to effect de-implementation of low-value ADT prescribing in localized prostate cancer. TRIAL REGISTRATION: ClinicalTrials.gov , NCT03579680.

5.
JCO Oncol Pract ; 16(6): e498-e506, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32369408

RESUMEN

PURPOSE: This study was designed to examine the impact of marital status on racial disparities in esophageal cancer care. PATIENTS AND METHODS: We performed a secondary analysis of data collected from the state cancer registry maintained by the Michigan Department of Health and Human Services. We identified patients with an esophageal cancer diagnosis between January 1, 2000, and December 31, 2013. χ2 test and logistics regression were used to analyze 6,809 patients who met our eligibility criteria. Statistical significance was defined as P ≤ .05. RESULTS: Approximately 88.4% of our patients were White and 11.6% were Black. A significantly higher number of White patients were married when compared with Blacks (62.9% v 31.8%, respectively; P < .0001). There was no significant difference in cancer staging between the 2 groups (P = .0671). Married Blacks had similar rates of esophagectomy, chemotherapy, and radiation as married Whites. Both single groups had lower rates of esophagectomy and chemotherapy than married Whites, but single Blacks were the least likely to undergo esophagectomy. Single patients were more likely to refuse treatment. CONCLUSION: Marital status differs significantly in Black and White patients with esophageal cancer and may help explain racial disparities in cancer care. Further research is needed to explore reasons for care underutilization in single patients and whether these differences translate into clinical outcomes.


Asunto(s)
Negro o Afroamericano , Neoplasias Esofágicas , Neoplasias Esofágicas/terapia , Humanos , Estado Civil , Michigan/epidemiología , Población Blanca
6.
Urology ; 136: 202-211, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31801683

RESUMEN

OBJECTIVE: To characterize the current landscape and future directions of academic benign prostatic hyperplasia (BPH) by using bibliometric analysis. METHODS: We used the Web of Science Core Collection to conduct a bibliometric analysis of leading BPH articles. Bibliometric analyses are quantitative approaches examining the impact of academic literature. We used the following search terms and Boolean logic "("benign prostat*") AND (hyperplasia OR enlarg*)" and characterized the 100 most-cited BPH articles through 2018 including citations, journal, author, year, and country. RESULTS: The top 100 BPH articles were published between 1978 and 2012. Citations ranged from 153 to 2171 across 27 different journals, including 10 urology-specific journals. The Journal of Urology was the most published journal (n = 25), followed by European Urology (n = 17), and Urology (n = 15). In general, the oldest 10 articles focused on BPH etiology/pathogenesis, while the newest 10 focused on treatment. The 1990's was the most productive decade with nearly half of the top 100 articles (n = 44). Twenty-six different countries contributed to the top 100 articles, with the US (n = 74), Italy (n = 19), and Canada (n = 12) being the most common. CONCLUSION: This study represents the first bibliometric analysis of the leading BPH articles impacting the academic literature. The focus has evolved from BPH pathogenesis to treatment, perhaps reflecting a shift in research funding and capacity. These findings may guide research priorities for this increasingly common condition.


Asunto(s)
Bibliometría , Hiperplasia Prostática , Edición/estadística & datos numéricos , Urología , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...